Coronavirus Update: iSPOCs, Fake Drugs & Data Protection Concerns

 
• By Ian Schofield
  
Generate a summary of this article
Listen to this article
Beta

In addition to our daily in-depth coverage of key events relating to the COVID-19 pandemic, we’re bringing you a periodic round-up of other developments. This edition covers events at EU and member state level, as well as initiatives by international regulators.

Covid19_Stamp_WorldMap
National actions continue in an effort to stem the spread of the coronavirus • Source: Shutterstock

With the pandemic continuing its deadly spread, individual countries are taking steps to address the growing number of COVID-related drug shortages, and regulator-industry cooperation is the order of the day. The increased risk of fake and unlicensed medical products has been highlighted, as have concerns about the data protection aspects of using technology to understand the spread of the coronavirus.

Supplies of vital medicines used for treating hospitalized COVID-19 patients are beginning to run dry in some EU member states....

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from Europe

  • EU Biosimilar Filings, Opinions And Approvals

     
    • By Saba Afreen

    <p>Executive Summary</p> <p>A list of EU biosimilar filings, CHMP opinions and EU marketing authorizations, including details of the biosimilar company, the brand name/INN, indication(s), the reference product/company, and the date and type of event.</p>

  • EU Pharma Reform: What You Need to Know Now

     
    • By Anabel Costa-Ferreira and Ian Schofield

    As the reform of the EU pharmaceutical legislation progresses through the legislative process, the Pinks Sheet offers an infographic highlighting some of the key changes being proposed that will reshape the way drug companies run their business.

  • New EU Approvals

    <p>Executive Summary<p> <p>The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add six new products, incl/ding Ixchiq, Valneva's chikungunya virus vaccine</p>

More from Geography